Among cases of FLT3-ITD-negative and NPM1-mutated CN-AML, IDH-1/IDH-2 mutations have been shown to improve OS.6 However a recent study of 826 patients with known IDH-1 and IDH-2 status found no prognostic impact on treatment response or OS.38 Further analysis is required to delineate the role of DNA-related genes in OS and treatment response. This evidence concerns the gene FLT3 and acute myeloid leukemia.